We use cookies and similar technologies to improve your website experience and help us understand how you use our website. By continuing to use this website, you consent to the usage of cookies. Learn more about our Privacy Statement and Cookie Policy.
In the Hill, Satya Marar writes op-ed about pandemic-era price fixing and how it negatively affects the progression of American pharmaceutical companies